Kintara Therapeutics shares are trading higher after the company secured $2 million National Institutes Of Health SBIR grant to support development of REM-001.
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics has secured a $2 million grant from the National Institutes Of Health SBIR to support the development of REM-001. This has led to an increase in the company's share prices.
June 29, 2023 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kintara Therapeutics' stock price is trading higher after the company secured a $2 million grant for REM-001 development.
The news of Kintara Therapeutics securing a $2 million grant from the National Institutes Of Health SBIR for the development of REM-001 has positively impacted the company's stock price. This is because the grant not only provides financial support for the development of REM-001, but also validates the potential of the product, which can boost investor confidence in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100